Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Regentis Biomaterials reported strong surgeon interest in GelrinC at the 8th ICRS Summit held October 8-10, 2026, in Porto, Portugal. GelrinC is a CE Mark-approved, cell-free hydrogel implant for knee cartilage repair, delivered in a single ~10-minute procedure; Phase II data showed approximately 100% greater KOOS score improvement versus historical microfracture controls at two years. The company is translating physician interest into broader European clinical adoption while its U.S. FDA pivotal trial, supported by European sites, has completed over 50% enrollment in an estimated 470,000-case annual U.S.
Key figures
- Drug Name
- GelrinC
- Phase Of Trial
- pivotal FDA study (>50% enrolled)
- Procedure duration
- approximately 10 minutes
- Fda trial enrollment
- over 50% complete
- Us annual addressable cases
- 470000
- Koos improvement vs microfracture
- approximately 100% greater at two years
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.